Ipca Laboratories Profile
Key Indicators
- Authorised Capital ₹ 57.60 Cr
- Paid Up Capital ₹ 25.37 Cr
- Company Age 75 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2,541.54 Cr
- Satisfied Charges ₹ 2,002.16 Cr
- Revenue Growth 8.62%
- Profit Growth -41.94%
- Ebitda -26.67%
- Net Worth 6.41%
- Total Assets 13.13%
About Ipca Laboratories
Ipca Laboratories Limited (ILL) was founded in India on 19 October 1949 and has a glorious history of 75 years and three months. Its registered office is in Mumbai, Maharashtra, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524494 and on the National Stock Exchange(NSE) under IPCALAB.
The Corporate was formerly known as The Indian Pharmaceutical Combine Association Ltd. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 57.60 Cr and a paid-up capital of Rs 25.37 Cr.
The company currently has active open charges totaling ₹2,541.54 Cr. The company has closed loans amounting to ₹2,002.16 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Ipca Laboratories Limited India are Harish Kamath as COMPANY SECRETARY and Ajit Jain as Cfo. Ajit Jain, Premchand Godha, Prashant Godha, and Five other members serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
Industry
What products or services does Ipca Laboratories Limited offer?
Ipca Laboratories Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Anti Inflammatory and Immunosuppressant API, Antiallergic API, Pharma & Bioanalytical Services, Pharmaceutical Services, API (Active Pharmaceutical Ingredients), Chemical Reagents & Catalysts, Amine Compounds, Drug Development Services, Charity & Non Profit Organizations.
Who are the key members and board of directors at Ipca Laboratories?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ajit Jain
|
Managing Director | 21-Aug-2009 | Current |
|
Pranay Godha
|
Managing Director | 11-Nov-2008 | Current |
|
Harish Kamath
|
Company Secretary | 20-Sep-1993 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Narendra Mairpady
|
Director | 20-Oct-2022 | Current |
|
Kamal Seth
|
Director | 29-Mar-2019 | Current |
|
Premchand Godha
|
Whole-Time Director | 31-Jan-2012 | Current |
|
Prashant Godha
|
Director | 28-Jul-2011 | Current |
|
Vivek Shiralkar
|
Director | 16-Jul-2024 | Current |
|
Swati Patankar
|
Director | 11-Mar-2024 | Current |
Financial Performance of Ipca Laboratories.
Ipca Laboratories Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 8.62% increase. The company also saw a substantial fall in profitability, with a 41.94% decrease in profit. The company's net worth moved up by a moderate rise of 6.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ipca Laboratories?
In 2023, Ipca Laboratories had a promoter holding of 46.29% and a public holding of 53.71%. The company had 2 Subsidiaries, 2 Joint Ventures and 2 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Vardhman Trusteeship Private LimitedNarendra Mairpady is a mutual person
-
Equippp Social Impact Technologies LimitedNarendra Mairpady is a mutual person
-
Ipca FoundationAjit Jain, Premchand Godha and 2 more are mutual person
-
Indo-Vietnamese Chamber Of Commerce And IndustryKamal Seth is a mutual person
-
Fibre Foils LimitedNarendra Mairpady is a mutual person
-
Gufic Biosciences LimitedKamal Seth is a mutual person
Charges (Loans)
₹2,541.54 Cr
₹2,002.16 Cr
Charges Breakdown by Lending Institutions
- Idbi Trusteeship Services Limited : 1510.00 Cr
- Hdfc Bank Limited : 691.22 Cr
- The Hongkong And Shanghai Banking Corporation Limited : 123.71 Cr
- Jp Morgan Chase Bank, N.A. : 114.21 Cr
- Kotak Mahindra Bank Limited : 29.70 Cr
- Others : 72.71 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Aug 2023 | Hdfc Bank Limited | ₹300.00 Cr | Open |
| 08 Aug 2023 | The Hongkong And Shanghai Banking Corporation Limited | ₹123.71 Cr | Open |
| 07 Oct 2022 | Hdfc Bank Limited | ₹391.22 Cr | Open |
| 02 Aug 2022 | Jp Morgan Chase Bank, N.A. | ₹114.21 Cr | Open |
| 25 Mar 2022 | Others | ₹1.90 Cr | Open |
How Many Employees Work at Ipca Laboratories?
Ipca Laboratories has a workforce of 18684 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ipca Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ipca Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
